Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 2Phase 1 2Phase EARLY_PHASE1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Breast Neoplasms 7Stomach Neoplasms 3Lung Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Ovarian Neoplasms 2Multiple Myeloma 2Carcinoma, Transitional Cell 2Carcinoma, Renal Cell 2Brain Neoplasms 2Uterine Cervical Neoplasms 1Unspecified Adult Solid Tumor, Protocol Specific 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms 1Neoplasm Metastasis 1Meningioma 1Melanoma 1Lymphoma, Large B-Cell, Diffuse 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Head and Neck Neoplasms 1Glioblastoma 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Ovarian Epithelial 1

Interventions

Nivolumab 9pembrolizumab 6Ipilimumab 5Magnetic Resonance Spectroscopy 3resiquimod 2encorafenib 2binimetinib 2aldesleukin 2Oncolytic Virotherapy 2MART-1 Antigen 2Interleukin-2 2Cyclophosphamide 2urelumab 1tremelimumab 1tetraethylpyrazine 1technetium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1relatlimab 1montanide ISA 51 1glucopyranosyl lipid-A 1fludarabine phosphate 1fludarabine 1durvalumab 1clevudine 1cemiplimab 1avelumab 1Specimen Handling 1Sentinel Lymph Node Biopsy 1S 28463 1Radiotherapy 1Radiation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Melanoma × Fluorodeoxyglucose F18 × Clear all
NCT01666353 2019-02-08

PET Quantitative Assessments of Solid Tumor Response to Immune Checkpoint Blockade Therapy

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase EARLY_PHASE1 Completed
20 enrolled
DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡